Abstract
Background and Purpose: Precise in vivo measurement of deep GM volume change is a highly demanded prerequisite for an adequate evaluation of disease progression and new treatments. However, quantitative data on the reproducibility of deep GM structure volumetry are not yet available. In this paper we aim to investigate this reproducibility using a large multicenter dataset. MATERIALS AND METHODS: We have assessed the reproducibility of 2 automated segmentation software packages (FreeSurfer and the FMRIB Integrated Registration and Segmentation Tool) by quantifying the volume changes of deep GM structures by using back-to-back MR imaging scans from the Alzheimer Disease Neuroimaging Initiative's multicenter dataset. Five hundred sixty-two subjects with scans at baseline and 1 year were included. Reproducibility was investigated in the bilateral caudate nucleus, putamen, amygdala, globus pallidus, and thalamus by carrying out descriptives as well as multilevel and variance component analysis. Results: Median absolute back-to-back differences varied between GM structures, ranging from 59.6-156.4 L for volume change, and 1.26%-8.63% for percentage volume change. FreeSurfer had a better performance for the outcome of longitudinal volume change for the bilateral amygdala, putamen, left caudate nucleus (P < .005), and right thalamus (P < .001). For longitudinal percentage volume change, Freesurfer performed better for the left amygdala, bilateral caudate nucleus, and left putamen (P.001). Smaller limits of agreement were found for FreeSurfer for both outcomes for all GM structures except the globus pallidus. Our results showed that back-to-back differences in 1-year percentage volume change were approximately 1.5-3.5 times larger than the mean measured 1-year volume change of those structures. CONCLUSIONS: Longitudinal deep GM atrophy measures should be interpreted with caution. Furthermore, deep GM atrophy measurement techniques require substantially improved reproducibility, specifically when aiming for personalized medicine.
| Original language | English |
|---|---|
| Pages (from-to) | 46-53 |
| Number of pages | 8 |
| Journal | American Journal of Neuroradiology |
| Volume | 39 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2018 |
Funding
Received June 16, 2017; accepted after revision August 28. From the Departments of Radiology and Nuclear Medicine (A.M., H.A., M.D.S., R.A.v.S., K.S.C., H.V.) and Epidemiology and Biostatistics (A.M., M.A.J.), Vrije University Medical Center, Amsterdam, The Netherlands; and the Neuroscience Research Center, Institute of Neuropharmacology (H.A.), Kerman University of Medical Sciences, Kerman, Iran. This work was supported by the Alzheimer Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and Department of Defense ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Disclosures: Marianne Jonker—UNRELATED: Consulting Fee or Honorarium: Vrije University Medical Center, Department of Epidemiology and Biostatistics, Comments: as a common practice, our department is paid for doing consultancy*. Ronald van Schijndel—OTHER RELATIONSHIPS: Image Analysis Center (IAC), Comments: partly working for the IAC, which is a contract research organization of the Vrije University Medical Center. Keith Cover—UNRELATED: Grants/Grants Pending: European Community FP7 Project, Comments: funded by the Neugrid4you project (grant agreement 2835262) from 2011 to 2015; studied methods for measuring atrophy of the brain in MRI*. Hugo Vrenken—UNRELATED: Grants/Grants Pending: Novartis Pharma, Comments: brain atrophy in MS; Teva Europe, Comments: brain atrophy in MS; Merck Serono, Comments: brain atrophy and lesions in MS*. *Money paid to the institution.
| Funders | Funder number |
|---|---|
| National Institute on Aging | U01AG024904 |
| Seventh Framework Programme | 2835262 |
